POST-TEST

Striving for Consensus: Current and Future Management of HER2-Low and HER2-Ultralow Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **How is HER2-ultralow breast cancer defined?**
   a. HER2 IHC 0 with ≤1% staining
   b. HER2 IHC 0 with ≤5% staining
   c. HER2 IHC 0 with ≤10% staining
   d. HER2 IHC 1+
   e. HER2 IHC 1+ or 2+

2. **Which of the following best describes progression-free survival (PFS) with T-DXd versus chemotherapy by time to progression on first-line CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) in the Phase III DESTINY-Breast06 trial for patients with HER2-low and HER2-ultralow metastatic breast cancer (mBC)?**
   a. T-DXd improved PFS only in patients who experienced disease progression after <6 months on first-line ET and CDK4/6i
   b. T-DXd improved PFS only in patients who experienced disease progression after <12 months on first-line ET and cDK4/6i
   c. T-DXd improved PFS only in patients who experienced disease progression after >12 months on first-line ET and CDK4/6i
   d. T-DXd improved PFS regardless of time to progression on first-line ET and CDK4/6i

3. **Which of the following any-grade adverse events was most commonly observed with T-DXd in patients with previously treated HR-positive, HER2-low or HER2-ultralow mBC in the Phase III DESTINY-Breast06 trial?**
   a. Neutropenia
   b. Nausea
   c. Keratitis
   d. Headache

4. **Which of the following best reflects the FDA approval status of T-DXd for patients with HER2-low breast cancer?**
   a. T-DXd is not approved for any patients with HER2-low disease
   b. T-DXd is approved only as first-line therapy for advanced HER2 IHC 2+ disease
   c. T-DXd is approved only for patients with HER2 IHC 2+ disease who received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
   d. T-DXd is approved for patients with HER2 IHC 1+ or 2+ disease who received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy

5. **What was the approximate reduction in the risk of disease progression or death with T-DXd versus treatment of physician's choice for patients with previously treated HR-positive, HER2-ultralow mBC in the Phase III DESTINY-Breast 06 trial?**
   a. 6%
   b. 11%
   c. 22%
   d. 47%